Cases
Cases
Mariner Health Central’s Chapter 11 restructuring reached approval of the Parkview facility sale on June 5, 2023, under the sale order Dkt. 601. Consummation of the authorized sale was the next transaction milestone after approval; a closing date is not established.
Mariner Health Central, Inc.’s Chapter 11 proceeding reached court approval of the Parkview facility sale on June 5, 2023, through the sale order Dkt. 601. That approval established an asset-sale milestone following the debtors’ initial pursuit of a negotiated restructuring. Consummation of the authorized transaction was the next material step after approval; a completed sale or subsequent plan outcome is not established.
Mariner Central filed its Chapter 11 petition Dkt. 1 on September 19, 2022, alongside the Parkview entities. According to the Perkins declaration Dkt. 12, Mariner Central supplied administrative, clinical and operational support to a California network of 20 skilled nursing facilities with approximately 2,190 licensed beds and 3,100 workers. Parkview operated a 121-bed facility in Hayward. Mariner Central earned a monthly support-services fee equal to 5% of facility net operating revenues, while approximately 85% of Parkview’s receipts came from Medicare and Medi-Cal.
The Perkins declaration Dkt. 12 identified the Ledesma litigation judgment as the principal filing catalyst: the judgment was reduced to $8,072,860.08, with an additional $6.6 million in attorneys’ fees and costs. Litigation pressure coincided with deteriorating operations attributed largely to the COVID-19 pandemic and Parkview’s role as a COVID center. Parkview moved from $1.4 million in net income in 2020 to a $4.826 million net loss in 2021; Mariner Central reported a $3.37 million net loss in 2021.
At filing, the debtors sought negotiated settlements, particularly with the Ledesma judgment plaintiffs, while maintaining resident care. The Perkins declaration Dkt. 12 described outreach to 25 potential postpetition lenders and projected $4,189,222 in cumulative negative cash flow for September 23 through December 16, 2022. Those liquidity pressures explain the need for a restructuring solution; the later Parkview sale approval is the operative transaction development.
Updated Oct 3
| Month | Filings |
|---|---|
| September 2022 | 56 |
| October 2022 | 179 |
| November 2022 | 125 |
| December 2022 | 68 |
| January 2023 | 65 |
| February 2023 | 39 |
| March 2023 | 42 |
| April 2023 | 38 |
| May 2023 | 41 |
| June 2023 | 46 |
| July 2023 | 40 |
| August 2023 | 20 |
| September 2023 | 52 |
| October 2023 | 57 |
| November 2023 | 11 |
| December 2023 | 0 |
| January 2024 | 0 |
| February 2024 | 0 |
| March 2024 | 0 |
| April 2024 | 0 |
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
| December 2025 | 0 |
| January 2026 | 0 |
| February 2026 | 0 |
| March 2026 | 0 |
| April 2026 | 3 |
| May 2026 | 0 |
| June 2026 | 1 |
| July 2026 | 3 |
| August 2026 | 0 |
| September 2026 | 0 |
| October 2026 | 3 |
| November 2026 | 0 |
Case facts and filing dates come from court records.Case docket on PACER